Lenzings, Lifeline

Lenzing's €300 Million Lifeline: Rights Issue Math, a Berenberg Downgrade, and the Fight for 14 Euros

Published on 10/03/2026 at 18:40 | Editorial boerse-global.de

Lenzing shares slid 28% as the stock traded ex-rights for its €300M capital increase; Berenberg downgraded to Hold and cut its target to €17.00.

Lenzing Stock Falls 28% on Ex-Rights Day as Berenberg Cuts to Hold
Lenzing's €300 Million Lifeline: Rights Issue Math, a Berenberg Downgrade, and the Fight for 14 Euros Illustration mit AI erstellt.

Lenzing's shareholders got a blunt lesson in dilution arithmetic last Friday. The Austrian fiber maker's stock closed at €14.02, a drop of 28% on the session — but the headline number tells only part of the story. A large chunk of that decline was mechanical, the inevitable consequence of the stock trading ex-rights for the first time. The rest reflected something harder to quantify: a market losing faith in the turnaround story.

The €300 Million Fix

To shore up its balance sheet, Lenzing has launched a fully guaranteed cash capital increase targeting gross proceeds of roughly €300 million. The company will issue 34,756,362 new shares at a subscription price of €8.65 apiece, lifting its share capital from just over €40.1 million to approximately €76.2 million. The subscription ratio of 10-for-9 means existing holders must commit fresh capital or watch their stakes shrink.

That €8.65 price represents a 42.50% discount to the theoretical ex-rights value — a concession that speaks volumes about the pressure behind the recapitalization. Major shareholders have lined up behind the plan: the B&C Group and Suzano have committed to subscribing for 18,159,291 new shares on a pro-rata basis, with Suzano pledging around €22.5 million in total. Suzano is also selling subscription rights for 1,757,754 shares to a B&C entity. Separately, Goldman Sachs Asset Management disclosed that NN shareholders intend to place existing shares without subscription rights, aiming to raise roughly €18 million net.

The transaction is watertight on paper. Whether it restores confidence is another matter entirely.

Should investors sell immediately? Or is it worth buying Lenzing?

Berenberg's Blunt Reassessment

The same day the stock went ex-rights, Berenberg stripped Lenzing of its buy rating, downgrading the shares from "Buy" to "Hold" and slashing its price target from €29.50 to €17.00. The move carried more psychological weight than the rights adjustment itself. When an analyst house cuts its fair-value estimate by more than 40% in one stroke, the recovery narrative loses its footing.

Berenberg's rationale centered on a stubbornly weak operating performance. Prices for viscose and cotton have been climbing, yet that tailwind has not translated into Lenzing's earnings as hoped. According to media reports, the bank also trimmed its 2026 EBITDA forecast to €55 million, citing looming pressure from raw material costs and restructuring charges. Doubts are also mounting about Suzano's future commitment — whether the Brazilian giant will deepen its engagement beyond exercising its existing rights. The core shareholders, including B&C, Suzano, and Oberbank AG, have all committed to fully exercise their subscription rights, which secures the €300 million raise. But the market is asking what happens after that.

A Chart That Tells the Story

Friday's slide carved out a new 52-week low of €13.68. The gap to the 52-week high of €29.75 now stands at 53%. The stock's close of €14.02 leaves it hovering barely above the prior 52-week trough of €13.14 — a level that suddenly looks less like a floor and more like a waypoint.

For retail investors, the capital increase cuts both ways. On one hand, the guaranteed liquidity injection is real: the 10-for-9 ratio and the anchor shareholders' binding commitments mean the €300 million is fully secured. On the other, the dilution is severe, and the operational problems Berenberg flagged remain untouched. If rising fiber prices can no longer lift margins and earnings meaningfully, the crisis runs deeper than a liquidity shortfall.

What Comes Next

The subscription window opens on Tuesday, 6 October 2026, and runs through 20 October 2026. Rights trading is scheduled for 6 to 14 October 2026. Those two weeks will reveal how much conviction the free float actually has in the restructuring plan. Clarity on the operating picture arrives on 5 November 2026, when Lenzing publishes its third-quarter results — the first hard look at how raw material costs and restructuring charges are weighing on the bottom line.

Lenzing has bought itself breathing room. The fundamental repair job has barely started.

Ad

Lenzing Stock: New Analysis - 3 October

Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Lenzing analysis...

Disclaimer...

en | AT0000644505 | LENZINGS | boerse | 70221370 |